EA201170682A1 - Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr - Google Patents

Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr

Info

Publication number
EA201170682A1
EA201170682A1 EA201170682A EA201170682A EA201170682A1 EA 201170682 A1 EA201170682 A1 EA 201170682A1 EA 201170682 A EA201170682 A EA 201170682A EA 201170682 A EA201170682 A EA 201170682A EA 201170682 A1 EA201170682 A1 EA 201170682A1
Authority
EA
Eurasian Patent Office
Prior art keywords
small cell
cell lung
cancer
inhibitor
lung cancer
Prior art date
Application number
EA201170682A
Other languages
English (en)
Other versions
EA018624B1 (ru
Inventor
Сандаруван Джиджанейдж
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201170682A1 publication Critical patent/EA201170682A1/ru
Publication of EA018624B1 publication Critical patent/EA018624B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

В настоящем изобретении предложена комбинированная терапия, включающая соединение 4-[4-[4-(4-фтор-3-трифторметилфенил)-1-метил-1Н-имидазол-2-ил]пиперидин-1-ил]-1Н-пиразоло[3,4-d]пиримидин или его фармацевтически приемлемую соль и ингибитор EGFR, для применения для лечения мультиформной глиобластомы, аденокарциномы толстой кишки, немелкоклеточного рака легких, мелкоклеточного рака легких, резистентного к цисплатину мелкоклеточного рака легких, рака яичников, лейкемии, рака поджелудочной железы, рака простаты, карциномы молочной железы, почечно-клеточной карциномы, множественной миеломы, саркомы Капоши, лимфомы Ходжкина, лимфангиолейомиоматоза, неходжкинской лимфомы или саркомы.
EA201170682A 2008-11-11 2009-11-04 Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr EA018624B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327608P 2008-11-11 2008-11-11
PCT/US2009/063189 WO2010056575A1 (en) 2008-11-11 2009-11-04 P70 s6 kinase inhibitor and egfr inhibitor combination therapy

Publications (2)

Publication Number Publication Date
EA201170682A1 true EA201170682A1 (ru) 2011-10-31
EA018624B1 EA018624B1 (ru) 2013-09-30

Family

ID=41664868

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170682A EA018624B1 (ru) 2008-11-11 2009-11-04 Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr

Country Status (11)

Country Link
US (1) US8334293B2 (ru)
EP (1) EP2355821A1 (ru)
JP (1) JP2012508240A (ru)
KR (1) KR20110075015A (ru)
CN (1) CN102209538B (ru)
AU (1) AU2009314336B2 (ru)
BR (1) BRPI0921888A2 (ru)
CA (1) CA2743295A1 (ru)
EA (1) EA018624B1 (ru)
MX (1) MX2011005002A (ru)
WO (1) WO2010056575A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970201B1 (en) 2013-03-11 2019-06-19 Merck Patent GmbH 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
US20140255471A1 (en) 2013-03-11 2014-09-11 Wake Forest University Health Sciences Method of treating brain tumors
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
ES2890556T3 (es) * 2014-04-04 2022-01-20 Astrazeneca Ab Combinación de inhibidor de EGFR e inhibidor de MEK para su uso en el tratamiento del cáncer con mutación de NRAS
EP3749290A4 (en) * 2018-01-29 2022-01-26 Jonathan Sackner-Bernstein METHODS OF DOPAMINE MODULATION IN HUMAN NEUROLOGICAL DISEASES
DE102018205152A1 (de) 2018-04-05 2019-10-10 Glatt Ingenieurtechnik Gmbh Verfahren und Reaktor zur Herstellung von Partikeln

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) * 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
CA2626456C (en) * 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EA018624B1 (ru) 2013-09-30
JP2012508240A (ja) 2012-04-05
MX2011005002A (es) 2011-05-25
AU2009314336A1 (en) 2010-05-20
WO2010056575A1 (en) 2010-05-20
US20110207752A1 (en) 2011-08-25
CN102209538B (zh) 2013-06-12
CN102209538A (zh) 2011-10-05
CA2743295A1 (en) 2010-05-20
US8334293B2 (en) 2012-12-18
AU2009314336B2 (en) 2013-09-12
BRPI0921888A2 (pt) 2015-12-29
EP2355821A1 (en) 2011-08-17
KR20110075015A (ko) 2011-07-05

Similar Documents

Publication Publication Date Title
EA201170682A1 (ru) Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr
CY1119844T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
TW200607505A (en) Fused heterocyclic kinase inhibitors
TW200801006A (en) Fused bicyclic mTOR inhibitors
EA201391470A1 (ru) Замещенные соли 2,3-дигидроимидазо[1,2-c]хиназолина
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
NZ620020A (en) Heterocyclic compounds and uses thereof
TN2010000236A1 (en) Fused pyridine pyrimidine and triazine compounds as cell cycle inhibitors
MX2007001289A (es) Piridinas condensadas como inhibidores de cinasa.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
WO2010025872A3 (en) Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
UA104731C2 (ru) Ингибиторы р38 мар-киназ
MY159230A (en) P38 map kinase inhibitors
MY153727A (en) Pyridazinone derivatives
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MY156210A (en) Compounds and methods for kinase modulation, and indications therefor
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
DK1781296T3 (da) Quinazolinderivater og deres anvendelse ved behandlingen af thrombocytæmi
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
CR10995A (es) Inhibidores de la actividad de akt
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU